Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting [Yahoo! Finance]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
Moleculin Biotech files to sell 6.37M shares of common stock for holders [Seeking Alpha]
Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.